Abstract
The search for new strategies to improve not only HDL-cholesterol levels but also to promote more efficient reverse cholesterol transport is justified by the marked antiatherogenic and antioxidant effects of high-density lipoprotein (HD L) particles. The present article reviews the drugs tested in animal research that have been shown to be capable of increasing cholesterol efflux (LXR agonists), promoting HDL-cholesterol uptake by the liver (partial inactivators of SRB1) or increasing the antioxidant (antiinflammatory) capacity of HDL (D4F, apo A-I mimetics). Only the latter, together with apo A-I Milano infusion and administration of a PPARα/γ (aleglitazar) have been evaluated in humans and have shown promising results, thus justifying investment in further research in this field.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
